NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.
Cambridge, MA
Joined November 2022
- Tweets56
- Following7
- Followers36
- Likes1
NextPoint Therapeutics retweeted
NextPoint's new checkpoint target, HHLA2, could extend immunotherapy’s reach by working where PD-1 blockers don't: a BioCentury Emerging Company Profile buff.ly/47QnmOp